Modifying Immunity in Children With DihydROartemisinin-Piperaquine (MIC-DroP)


I'm Interested

Trial ID: NCT04978272


The MIC-DroP trial will test the hypothesis that preventing early life blood-stage malaria antigenic exposure with intermittent preventive therapy (IPT) enhances protective immunity to malaria. This study will take advantage of a unique opportunity to study infants born to mothers followed in a NIH-funded randomized controlled trial of novel intermittent preventive therapy in pregnancy (IPTp) regimens (NCT04336189). MIC-DroP will leverage the parent IPTp study to enroll 924 children who will be randomized at 8 weeks of age to receive no intermittent preventive therapy in childhood (IPTc), monthly DP from 8 weeks to 1 year of age, or monthly DP from 8 weeks to 2 years of age, and then follow children to 4 years of age. The primary outcome of this study will be to compare the incidence of malaria from 2 to 4 years of age among children randomized to receive no IPTc, monthly DP for the first year of life, or monthly DP for the first two years of life. Investigators will also leverage this trial to evaluate immune development during early childhood.

Official Title

Enhancing Immunity to Malaria in Young Children With Effective Chemoprevention

Stanford Investigator(s)

Prasanna Jagannathan

Assistant Professor of Medicine (Infectious Diseases) and of Microbiology and Immunology


Inclusion Criteria:

   1. Born to HIV-uninfected mother enrolled in parent clinical trial of intermittent
   preventative treatment of malaria in pregnancy (IPTp-SP vs. IPTp-DP vs. IPTp-SP+DP,
   NCT 04336189)

   2. Resident of Busia District

   3. Provision of informed consent by parent/guardian

   4. Agreement to present for any illness and avoid, where possible, medications outside
   the study protocol.

Exclusion Criteria:

   1. Intention of moving outside Busia district during the study period

   2. Active medical problem requiring in-patient evaluation or chronic medical condition
   requiring frequent medical attention


other: DP Placebo

drug: Dihydroartemisinin-piperaquine (DP)


I'm Interested

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Prasanna Jagannathan